Overview
Biologics have gained considerable traction around the globe owing to their capacity to assist in treatment, prevention, or even curing a multitude of medical conditions like cancer, chronic kidney disorder, cystic fibrosis, autoimmune diseases, and diabetes. These drugs can be classified into two major categories Chemicals and Non-chemicals. Chemicals like vitamins, minerals, herbal extracts, botanicals, hormones, proteins, and amino acids are known to induce various actions by interacting with external micro-organisms and organs. Hemophilia is a hereditary blood disease that is characterized by bleeding from the red blood cells. The Ayurvedic treatment of hemophilia is aimed at treating the comorbid condition of the disease and preventing recurrent bleeding.
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/4393
Drivers
Increased volume of research and development efforts for biologics to cater to the growing prevalence of CKD (chronic kidney disease), immunity disorders, cancer, and others is expected to augment growth of the MENA biologics & biosimilars market throughout the forecast period.
In addition to this, rising demand for biosimilars in the African countries owing to their affordability is expected to supplement growth of the MENA biologics & biosimilars market during the forecast period.
The Epitome of the COVID-19 Debacle
The inception of the COVID-19 virus has caused a barrier in the progress of the MENA biologics & biosimilars market. The pandemic-spurred restrictions have halted the development, approval, and launch of several products. Moreover, cancelation of international shipments as a result of travel bans at a cross-country level had negatively influenced the market during Q2 of 2020. However, the market is witnessing a revival with the withdrawal of lockdowns.
Competitive Landscape
Major companies contributing to the MENA biologics & biosimilars market are Pfizer, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-la Roche Ag, Takeda Pharmaceutical Company Limited, Sanofi S.A., and Amgen, Inc.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4393
Key Takeaways
The MENA biologics & biosimilars market is anticipated to grow at a CAGR of XX % during the forecast period owing to the increasing investments by the regional governments in the drug discovery process and growing prevalence of several diseases. For instance, in September 2021, a group of researcher from King Saud University Medical City have recommended the oncology centers in Saudi Arabia to use trastuzumab biosimilars in the treatment of breast cancer to reduce the medical costs associated with this condition.
In this cluster of regions, UAE (United Arab Emirates) is leading the pack of the MENA biologics & biosimilars market since the establishment of Emirates SkyCargo, a major air-transport company focused on supplying pharmaceutical products, which has reached a milestone of transporting (import as well as export) over 400,000 tons of pharmaceutical cargo as of September 2021.
Reasons to Purchase this Report
• Current and future of global MENA Biologics & Biosimilars market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
https://www.coherentmarketinsights.com/promo/buynow/4393
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By Region/Country
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Biologics & Biosimilars Overview
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Registered Products
- Patent Expiry Analysis
- Recombinant (Factor VIII) & Patient Population (Saudi Arabia)
- MENA Biologics & Biosimilars Market – Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- New Developments
- Strategies
- MENA Biologics & Biosimilars Market, By Product Type, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Influenza Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Factor VIII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Xyntha
- Octanate
- Kovaltry
- Advate
- Koate
- Adynovate
- Kogenate
- Hemlibra
- Elocta
- Recombinate
- Feiba
- Immunate
- Alphanate
- Novoeight
- Erythropoietin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Epoetin Alfa
- Binocrit
- 2000IU
- 4000IU
- Eprex
- 2000IU
- 4000IU
- Binocrit
- Darbepoietin Alfa (Aranesp)
- Epoetin Alfa-epbx (Retacrit, Recormon)
- Epoetin Alfa
- Aflibercept (EYLEA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Ziv-Aflibercept (ZALTRAP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- MENA Biologics & Biosimilars Market, By Therapeutic Application, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hemophilia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Age-related Macular Degeneration
- Introduction
- Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Kidney Diseases
- Introduction
- Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Influenza
- Introduction
- Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- MENA Biologics & Biosimilars Market, By Region/Country, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region/Country, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, By Region/Country, 2017 – 2027
- Regional/ Country Trends
- Gulf
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- Saudi Arabia
- UAE
- Kuwait
- Egypt
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Million)
- Introduction
- Competitive Landscape
- Company Profiles
- F. Hoffmann-la Roche Ag
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Amgen, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-la Roche Ag
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
Inquire more about this report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/4393
Our analysts are experts in this field with years of experience. We at Coherent Market Insights maintain the highest level of accuracy and transparency in the report. The primary and secondary resources used in the report are taken from reliable and high authority sources to deliver 100% accurate and trusted data.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837